好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Reduced Intrinsic Connectivity Secondary to Multiple Sclerosis as a Functional Marker of Impaired Verbal Memory Encoding and Retrieval
Multiple Sclerosis
P5 - Poster Session 5 (11:45 AM-12:45 PM)
19-010
We aimed to investigate the differences in cerebral intrinsic connectivity between people with multiple sclerosis (pwMS) and healthy controls (HC) and their associations with verbal memory.
In MS, multifocal lesions and widespread inflammation contribute to brain network changes, and structural disruptions lead to maladaptive functional reorganization with clinical implications. Verbal memory is common and debilitating in MS.

Included were 23 pwMS (median age 28.5yr, range 28–62; 42% female; median disease duration 1 year, range 0–11) and 10 HC (median age 28yr, range 20–48; 36% female). Participants underwent verbal memory assessment using the Wechsler Memory Scale-III and 3T MRI (T1-weighted MPRAGE, FLAIR, and resting-state functional MRI [rs-fMRI]). White matter lesions (WML) were semiautomatically segmented. Using rs-fMRI, whole-brain intrinsic connectivity (ICC) maps were estimated. Group-level analyses utilized a voxel-wise general linear model, with familywise correction at a p-FWE<0.05 cluster-size threshold.
PwMS exhibited  diffusely lower intrinsic connectivity (T = -4.35, p-FDR < 0.001). Voxel-wise meta-regression analysis of MS effect in ICC revealed association with areas related to reward (meta-analytic coactivation [r] = 0.25), motivation (r = 0.15), and working memory (r = 0.11). A generalized linear model adjusted for age, sex, WML volume, and disease duration revealed that the effect of MS in ICC was an independent predictor of poorer verbal learning in the immediate recall phase (B = -9.14, 95% CI [-15.61, -2.70], P = 0.006), delayed recall phase (B = -10.77, 95% CI [-19.99, -1.54], P = 0.022), and retention rate (B = -4.89, 95% CI [-8.86, -0.927], P = 0.0016).

MS is related to lower cerebral intrinsic connectivity, and this disruption secondary to MS is associated with worse verbal memory in both early and delayed phases of encoding and retrieval, unraveling the potential of resting-state intrinsic connectivity to be used as disease-related functional biomarker of working memory in multiple sclerosis.
Authors/Disclosures
Jonadab Dos Santos Silva, MD, PhD
PRESENTER 		Dr. Dos Santos Silva has nothing to disclose.
Viviane T. Carvalho, MD (Federal Fluminense University) Dr. Carvalho has nothing to disclose.
Vanessa Dias Veloso, MD (Yale New Haven Hospital) Dr. Dias Veloso has nothing to disclose.
Sarita Walvekar, MD Sarita Walvekar has nothing to disclose.
Luciana S. Azambuja, Sr., PhD Dr. Azambuja has nothing to disclose.
Adriana G. Pereira, PhD Dr. Pereira has nothing to disclose.
Giordani Passos Dr. Passos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AstraZeneca. Dr. Passos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Passos has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca. Dr. Passos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMS. Dr. Passos has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Passos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Passos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
Douglas K. Sato, MD Dr. Sato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Sato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra-Zeneca. The institution of Dr. Sato has received research support from Biogen. The institution of Dr. Sato has received research support from Merck.
Jefferson Becker, MD, PhD (WorldPharma) Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AMGEN. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ASTRAZENECA. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AMGEN. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MERCK. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ASTRAZENRCA. Dr. Becker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMS.